MedTrace Logo

The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

NCT03535883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 590

Last updated 2023-10-13

No results posted yet for this study

Summary

To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.

Conditions

  • Pleural Effusion
  • Thoracic Effusion

Interventions

DRUG

Novel Oral Anti-Coagulants

Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Kyle Bramley, MD · Yale University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2020-01-01
Completion
2020-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03535883 on ClinicalTrials.gov